Atopic Dermatitis

Primary Care - Clinics in Office Practice

Volumn 35, Issue 1, 2008, Pages 105-117

  Ong, Peck Y ^a   Boguniewicz, Mark ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE DIPROPIONATE; AMCINONIDE; AZATHIOPRINE; BENZODIAZEPINE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CHLORAL HYDRATE; CLOBETASOL PROPIONATE; CLONIDINE; CORTICOSTEROID; CYCLOSPORIN A; DESONIDE; DESOXIMETASONE; DIFLORASONE DIACETATE; DOXEPIN; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; FLUTICASONE PROPIONATE; HALCINONIDE; HYDROCORTISONE; HYDROCORTISONE VALERATE; IMMUNOGLOBULIN; METHOTREXATE; MOMETASONE FUROATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; TACROLIMUS; TRIAMCINOLONE ACETONIDE; ULOBETASOL PROPIONATE;

ATOPIC DERMATITIS; CORTICOSTEROID THERAPY; DRUG EFFECT; FOOD ALLERGY; HUMAN; HUMIDIFIER; IMMUNOTHERAPY; MICROBIAL COLONIZATION; PATHOGENESIS; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SKIN CARE; SLEEP DISORDER;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; CALCINEURIN; DERMATITIS, ATOPIC; HUMANS; PRURITUS; SKIN CARE;

EID: 38349010795     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2007.09.006     Document Type: Review

References (54)

1. Laughter D., Istvan J.A., Tofte S.J., et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 43 4 (2000) 649-655
2. Paller A.S., McAlister R.O., Doyle J.J., et al. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila) 41 5 (2002) 323-332
3. Lau S., Nickel R., Niggemann B., et al. The development of childhood asthma: lessons from the German Multicentre Allergy Study (MAS). Paedriatr Respir Rev 3 3 (2002) 265-272
4. Su J.C., Kemp A.S., Varigos G.A., et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 76 2 (1997) 159-162
5. Leung D.Y., Boguniewicz M., Howell M.D., et al. New insights into atopic dermatitis. J Clin Invest 113 5 (2004) 651-657
6. Hoffjan S., and Stemmler S. On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br J Dermatol 157 (2007) 441-449
7. Hudson T.J. Skin barrier function and allergic risk. Nat Genet 38 (2006) 399-400
8. Howell M.D., Kim B.E., Gao P., et al. Cytokine modulation of AD filaggrin skin expression. J Allergy Clin Immunol 120 (2007) 150-155
9. Schmid-Grendelmeier P., Simon D., Simon H.U., et al. Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 56 (2001) 841-849
10. Williams H.C., Burney P.G., Pembroke A.C., et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 131 (1994) 406-416
11. Lucky A.W., Leach A.D., Laskarzewski P., et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 14 4 (1997) 321-324
12. Chamlin S.L., Kao J., Frieden I.J., et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 47 2 (2002) 198-208
13. Abramovits W., Boguniewicz M., and Adult Atopiclair Study Group. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 5 3 (2006) 236-244
14. Bigliardi-Qi M., Lipp B., Sumanovski L.T., et al. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology 210 2 (2005) 91-99
15. Bigliardi P.L., Stammer H., Jost G., et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 56 6 (2007) 979-988
16. Kelsay K. Management of sleep disturbance associated with atopic dermatitis. J Allergy Clin Immunol 118 1 (2006) 198-201
17. Eigenmann P.A., Sicherer S.H., Borkowski T.A., et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 101 3 (1998) E8
18. Bock S.A. Diagnostic evaluation. Pediatrics 111 6 Pt 3 (2003) 1638-1644
19. Sampson H.A. Update on food allergy. J Allergy Clin Immunol 113 5 (2004) 805-819
20. Endo K., Hizawa T., Fukuzumi T., et al. Keeping dogs indoors aggravates infantile atopic dermatitis. Arerugi 48 12 (1999) 1309-1315
21. Darsow U., Vieluf D., and Ring J. Evaluating the relevance of aeroallergen sensitization in atopic eczema with the atopy patch test: a randomized, double-blind multicenter study. Atopy Patch Test Study Group. J Am Acad Dermatol 40 2 Pt 1 (1999) 187-193
22. Beltrani V.S. The role of house dust mites and other aeroallergens in atopic dermatitis. Clin Dermatol 21 3 (2003) 177-182
23. Tan B.B., Weald D., Strickland I., et al. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 347 (1996) 15-18
24. Oosting A.J., de Bruin-Weller M.S., Terreehorst I., et al. Effect of mattress encasings on atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the Dutch mite avoidance study. J Allergy Clin Immunol 110 3 (2002) 500-506
25. Arshad S.H., Bateman B., Sadeghnejad A., et al. Prevention of allergic disease during childhood by allergen avoidance: the Isle of Wight prevention study. J Allergy Clin Immunol 119 2 (2007) 307-313
26. Werfel T., Breuer K., Rueff F., et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61 (2006) 202-205
27. Boguniewicz M., Sampson H., Leung S.B., et al. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 108 4 (2001) 651-652
28. Ong P.Y., Ohtake T., Brandt C., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347 15 (2002) 1151-1160
29. Bunikowski R., Mielke M.E., Skarabis H., et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol 105 4 (2000) 814-819
30. Leung D.Y.M., Harbeck R., Bina P., et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 92 3 (1993) 1374-1380
31. Schmid-Grendelmeier P., Fluckiger S., Disch R., et al. IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol 115 (2005) 1068-1075
32. Boguniewicz M., Schmid-Grendelmeier P., and Leung D.Y.M. Atopic dermatitis. J Allergy Clin Immunol 118 1 (2006) 40-43
33. Weston W.L., Lane A.T., and Morelli J.G. Color textbook of pediatric dermatology. 2nd edition (1996), Mosby, St. Louis (MO) p. 358
34. Zuberbier T., Orlow S.J., Paller A.S., et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 118 (2006) 226-232
35. Friedlander S.F., Hebert A.A., Allen D.B., and Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 46 3 (2002) 387-393
36. Lucky A.W., Grote G.D., Williams J.L., et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 59 3 (1997) 151-153
37. Eichenfield L.F., Basu S., Calvarese B., et al. Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatr Dermatol 24 3 (2007) 289-295
38. Boguniewicz M., Fiedler V.C., Raimer S., et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 102 4 Pt 1 (1998) 637-644
39. Margolis D.J., Hoffstad O., and Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 214 4 (2007) 289-295
40. Arellano F.M., Wentworth C.E., Arana A., et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 127 4 (2007) 808-816
41. Paul C., Cork M., Ross A.B., et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 117 1 (2006) e118-e128
42. Fonacier L., Spergel J., Charlesworth E.N., et al. Report of the Topical Calcineurin Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 115 (2005) 1249-1253
43. Akdis C.A., Akdis M., Bieber T., et al., for the European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Group. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 118 (2006) 152-169
44. Forte W.C., Sumita J.M., Rodrigues A.G., et al. Rebound phenomenon to systemic corticosteroid in atopic dermatitis. Allergol Immunopathol (Madr) 33 (2005) 307-311
45. Boguniewicz M. Atopic dermatitis. Immunol Allergy Clinics N Am 22 (2002) 1-178
46. Williams H.C. Two "positive" studies of probiotics for atopic dermatitis: or are they?. Arch Dermatol 142 9 (2006) 1201-1203
47. Kalliomaki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. 2001;357:1076-9.
48. Taylor A.L., Dunstan J.A., and Prescott S.L. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol 119 1 (2007) 184-191
49. Williams H.C. Evening primrose oil for atopic dermatitis. BMJ 327 (2003) 1358-1359
50. Zhang W., Leonard T., Bath-Hextall F., et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev 2 (2005) CD002291
51. Krathen R.A., and Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53 2 (2005) 38-40
52. Vigo P.G., Girgis K.R., Pfuetze B.L., et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55 1 (2006) 168-170
53. Beck L.A., and Saini S. Wanted: a study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol 55 3 (2006) 540-541
54. Veien N.K., Busch-Sørensen M., and Stausbøl-Grøn B. Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 53 (2005) 147-149